Nasdaq
Infectious Disease Dx Firm Talis Biomedical Raises $254M in IPO
The firm offered 15,870,000 shares of its common stock, including 2,070,000 shares sold pursuant to the full exercise of the underwriters' option.
Interpace Biosciences Receives Nasdaq Delisting Notice, Initiates Restructuring
The notice was issued due to the company's extended period of non-compliance with the minimum $2.5 million stockholder's equity requirement for continued listing.
Lucira Health Files for $115M IPO
The company, which is developing instrument-free, low-cost molecular diagnostics platform for infectious disease testing, plans to float its shares on the Nasdaq.
Bionano Genomics Stock Soars on User Presentations, Public Stock Offering, Renewed Nasdaq Compliance
Buoyed by a string of positive news, the San Diego firm's stock was up 22 percent in Friday afternoon trading and 80 percent from last week.
Meridian Bioscience Preliminary Fiscal 2021 Q1 Revenues Up 94 Percent
Growth was driven by demand in its life science segment, particularly for COVID-19-related products, while the diagnostics segment saw uneven improvement.